Retatrutide in Type 2 Diabetes and the Kidney: From Phase 2 to TRANSCEND, and What Remains Unknown

RESEARCH · RETATRUTIDE · TYPE 2 DIABETES & KIDNEY

Retatrutide in Type 2 Diabetes and the Kidney: From Phase 2 to TRANSCEND, and What Remains Unknown

PurixLab’s Retatrutide 10mg is a research vial of the GIP, GLP-1 and glucagon receptor triple agonist. Our earlier articles cover the clinical trial overview, glucagon receptor biology, pharmacokinetics, single, dual and triple agonist comparisons and safety and tolerability. This article follows one population through the programme: people with type 2 diabetes. It traces the glycaemic and body-composition data from phase 1b to phase 3, then looks at what has been reported about the kidney and what the ongoing trials are designed to answer. These are published clinical-trial findings about an investigational drug used under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Phase 1b: early data in type 2 diabetes

A phase 1b multiple-ascending study in type 2 diabetes enrolled 72 participants at four US centres for 12 weeks, with placebo and dulaglutide 1.5 mg as comparators. Gastrointestinal disorders were the most frequent adverse events, pharmacokinetics were proportional across the tested range, and the half-life was approximately 6 days. Placebo-adjusted HbA1c fell significantly in the three highest groups, by up to 1.6%, and placebo-adjusted weight loss reached 8.96 kg [1].

Phase 2: glycaemic control and weight

The phase 2 trial randomised 281 adults with type 2 diabetes and an HbA1c of 7.0-10.5% at 42 US centres, comparing several retatrutide regimens with placebo and dulaglutide 1.5 mg. At 24 weeks, HbA1c changed by −2.02% in the 12 mg escalation group, against −0.01% with placebo and −1.41% with dulaglutide. At 36 weeks, body weight fell by 16.94% in the same group, compared with 3.00% on placebo and 2.02% on dulaglutide. Mild-to-moderate gastrointestinal events occurred in 35% of retatrutide-treated participants overall, ranging from 13% to 50% across groups, and there was no severe hypoglycaemia [2].

A body-composition substudy used dual-energy X-ray absorptiometry (DXA) in 189 participants, of whom 103 completed both baseline and week-36 scans. Total fat mass fell by 26.1% in the pooled 8 mg groups and 23.2% in the 12 mg group, against 4.5% with placebo, and the authors reported that the proportion of lean mass lost relative to weight lost was similar to other obesity treatments [3]. The small number of completed scans limits how far these results can be generalised.

Phase 3: TRANSCEND-T2D-1 and TRIUMPH-2

TRANSCEND-T2D-1 tested retatrutide as monotherapy in 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise, at 48 sites in the USA, Mexico and India. Baseline HbA1c was 7.9% and mean diabetes duration 2.5 years. At 40 weeks, HbA1c changed by −1.69%, −1.86% and −1.94% in the 4 mg, 9 mg and 12 mg groups versus −0.81% with placebo, and body weight by −11.5%, −13.9% and −15.3% versus −2.6%. Discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo, and no severe hypoglycaemia was reported [4].

TRIUMPH-2 enrolled 1152 adults with obesity and type 2 diabetes, with a mean BMI of 38.2 and mean HbA1c of 7.71%, and had body weight at week 80 as its primary endpoint. Weight changed by −11.9%, −16.8% and −18.8% in the 4 mg, 9 mg and 12 mg groups versus −5.1% with placebo. Dysesthesia (4%, 6% and 7% versus 1%) and hypotension were more frequent with retatrutide, and discontinuation due to adverse events or death was higher in the 9 mg (12%) and 12 mg (8%) groups than in the 4 mg group (4%) or placebo (5%) [5]. All of these trials were funded by the manufacturer [2,4,5].

Lipids and inflammatory markers

A post hoc biomarker analysis of the two phase 2 trials found reductions in atherogenic lipoproteins in both, including non-HDL cholesterol (up to −21.0% in the diabetes trial) and apolipoprotein B (−21.4%). High-sensitivity C-reactive protein fell by 54.8% in the trial without diabetes, but not in the diabetes trial [6]. These are surrogate markers rather than cardiovascular events.

What has been reported about the kidney

A post hoc analysis pooled kidney measures from the phase 2 diabetes trial (n = 281) and the phase 2 obesity trial (n = 338), both of which required an eGFR of at least 45. At baseline, mean creatinine-based eGFR was 91 and median urine albumin-to-creatinine ratio (UACR) 13 mg/g in the diabetes trial. In type 2 diabetes, the 12 mg group had a UACR reduction of 37.0% versus placebo at 36 weeks, while eGFR was unchanged. In the obesity trial, UACR fell by 28.0% and 31.5% in the 8 mg and 12 mg groups and creatinine-based eGFR rose by 5.3 and 8.5 units, with similar increases in cystatin C-based estimates. Because most participants had normal albuminuria, the absolute UACR reduction was modest [7].

Animal data point in a similar direction but are limited. In db/db mice treated for 10 weeks, retatrutide was the most effective of three incretin agents for diabetic kidney disease markers and body weight, while tirzepatide was most effective for blood glucose [8]. In a 21-day streptozotocin rat model, retatrutide lowered renal HIF-1α expression but did not produce statistically significant histopathological protection, and the authors note that this insulin-deficient model does not reflect type 2 diabetes [9].

The trials designed to answer the kidney question

TRANSCEND-CKD randomised 146 adults with overweight or obesity and chronic kidney disease (eGFR 25-75), 37.7% of whom had type 2 diabetes. Its primary endpoint is measured GFR by iohexol clearance at week 24, with MRI measures of kidney haemodynamics and of perirenal and renal sinus fat. At baseline, measured GFR was 49.3 and cystatin C-based eGFR 49.6, while creatinine-based eGFR was 64.2, illustrating how far estimated and measured values can diverge. The study is intended to inform the ongoing cardio-kidney outcome trial TRIUMPH-Outcomes [10]. Separately, the TRIUMPH programme comprises four phase 3 trials in more than 5800 participants covering weight management, obstructive sleep apnoea and knee osteoarthritis [11].

What remains unknown

  • Hard kidney and cardiovascular outcomes. Current kidney data are post hoc biomarker analyses in people with largely preserved function [7]; outcome data await TRIUMPH-Outcomes [10].
  • Kidney function in established disease. Whether eGFR changes reflect true filtration changes is what measured-GFR work is designed to test [10].
  • Comparative standing. A 2026 network meta-analysis of 102 trials in type 2 diabetes ranked retatrutide best for weight loss, but tirzepatide, orforglipron and semaglutide best for glycaemic control, and called for long-term high-quality trials [12].
  • Durability. The longest published diabetes data run to 80 weeks [5].

Retatrutide 10mg at PurixLab

Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Retatrutide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040 · doi:10.1016/S0140-6736(22)02033-5
  2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
  3. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PubMed 40609566 · doi:10.1016/S2213-8587(25)00092-0
  4. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PubMed 42250575 · doi:10.1016/S0140-6736(26)00967-0
  5. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PubMed 42810372 · doi:10.1016/S0140-6736(26)01861-1
  6. Ruotolo G, Harris C, Lin Y, et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. 2026;28(11):10183-10194. PubMed 42608321 · PMC13646367 · doi:10.1111/dom.71200
  7. Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025;10(6):1980-1992. PubMed 40630318 · PMC12231004 · doi:10.1016/j.ekir.2025.03.049
  8. Ma J, Hu X, Zhang W, et al. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. PubMed 39212900 · doi:10.1007/s12020-024-03998-8
  9. Keskin U, Altın E, Özatik FY, et al. Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile. J Mol Histol. 2026;57(6):343. PubMed 42878930 · doi:10.1007/s10735-026-11013-9
  10. Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026;41(6):1058-1068. PubMed 41160422 · PMC13218929 · doi:10.1093/ndt/gfaf230
  11. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. PubMed 41090431 · PMC12673447 · doi:10.1111/dom.70209
  12. Wu X, Yang Y, Cui X, et al. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials. Front Pharmacol. 2026;17:1846714. PubMed 42394981 · PMC13322860 · doi:10.3389/fphar.2026.1846714

Leave a Comment

Your email address will not be published. Required fields are marked *